Toceranib-d8
Toceranib-d8 is the deuterium labeled Toceranib. Toceranib (SU11654) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits PDGFR, VEGFR, and Kit with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively. Toceranib (SU11654) has antitumor and antiangiogenic activity, and used in the treatment of canine mast cell tumors[1][2].
Product Specifications
UNSPSC
12352005
Hazard Statement
H315, H319
Target
C-Kit; Isotope-Labeled Compounds; PDGFR; VEGFR
Type
Isotope-Labeled Compounds
Related Pathways
Others; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Purity
99.08
Solubility
10 mM in DMSO
Smiles
C(=C1C=2C(NC1=O)=CC=C(F)C2)C3=C(C)C(C(NCCN4C(C(C(C4([2H])[2H])([2H])[2H])([2H])[2H])([2H])[2H])=O)=C(C)N3
Molecular Formula
C22H17D8FN4O2
Molecular Weight
404.51
Precautions
H315, H319
References & Citations
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, protect from light, stored under nitrogen)
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-10330S/Toceranib-d8-SDS-MedChemExpress.pdf
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
CAS Number
[1795134-78-9]
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items